CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Open access
Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N · 2015 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have previously shown that PD-1 limits the efficacy of CTL to mediate immune control of metastatic osteosarcoma in the K7M2 mouse model of pulmonary metastatic disease and that blockade of PD-1/PD-L1 interactions can partially improve survival outcomes by enhancing the function of osteosarcoma-specific CTL. However, PD-1/PD-L1 blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells. We investigated the mechanism of tumor cell resistance after blockade, and additional combinational therapies to combat resistance. METHODS: We used an implantable model of metastatic osteosarcoma, and evaluated survival using a Log-rank test. Cellular analysis of the tumor was done post-mortem with flow cytometry staining, and evaluated using a T-test to compare treatment groups. RESULTS: We show here that T cells infiltrating PD-L1 antibody-resistant tumors upregulate additional inhibitory receptors, notably CTLA-4, which impair their ability to mediate tumor rejection. Based on these results we have tested combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade in the K7M2 mouse model of metastatic osteosarcoma and show that this results in complete control of tumors in a majority of mice as well as immunity to further tumor inoculation. CONCLUSIONS: Thus, combinational immunotherapy approaches to block additional inhibitory pathways in patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance to disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-015-0067-z

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Higher dose and longer duration of α-PD-L1 mAb treatment does not improve survival, suggesting resistance to α-PD-L1 mAb treatment. Mice were injected with K7M2 cells, and treated for either 15 days (n = 10) or 30 days (n = 10) with α-PD-L1 mAb. Survival was not significantly different between the 15 day and 30 day treatment, p = 0.2942, and all mice succumbed to disease (A). At time of necropsy, PD-L1, CD80, and CD86 expression was evaluated using Flow Jo. PD-L1 expression was significantly decreased in treated versus untreated mice, p = 0.0026. CD80 expression was significantly increased in treated versus untreated mice, p < 0.0001. CD86 expression was significantly increased in treated versus untreated mice, p < 0.0001 (B). At time of necropsy, PD-1+, CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.0005 (C). CTLA-4 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.043 (D). LAG3 + CD8+ expression was not significantly different between treated and untreated mice (E).
Figure 1 Higher dose and longer duration of α-PD-L1 mAb treatment does not improve survival, suggesting resistance to α-PD-L1 mAb treatment. Mice were injected with K7M2 cells, and treated for either 15 days (n = 10) or 30 days (n = 10) with α-PD-L1 mAb. Survival was not significantly different between the 15 day and 30 day treatment, p = 0.2942, and all mice succumbed to disease (A). At time of necropsy, PD-L1, CD80, and CD86 expression was evaluated using Flow Jo. PD-L1 expression was significantly decreased in treated versus untreated mice, p = 0.0026. CD80 expression was significantly increased in treated versus untreated mice, p < 0.0001. CD86 expression was significantly increased in treated versus untreated mice, p < 0.0001 (B). At time of necropsy, PD-1+, CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.0005 (C). CTLA-4 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.043 (D). LAG3 + CD8+ expression was not significantly different between treated and untreated mice (E).CC BY · PubMed Central
Figure 2 Naïve mice injected with in vivo treated α-PD-L1 mAb K7M2 cells are non-responsive to α-PD-L1 treatment, suggesting resistance to α-PD-L1 treatment. Naïve Balb/cJ mice were injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma, with decreased PD-L1 expression, (B) black histogram is PD-L1 expression prior to reimplantation in comparison to mock treated mice in white, and treated with α-PD-L1 mAb or mock (A). No significant difference was seen between survival in treated (n = 10) and untreated (n = 10) mice injected with treated metastatic osteosarcoma (C). PD-L1 expression on metastatic osteosarcoma from mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice was significantly decreased, p = 0.0026 (D). At time of necropsy, PD-1 + CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice, p = 0.0017 (E). CTLA-4 + CD8+ expression was significantly different in in vivo α-PD-L1 mAb treated metastatic osteosarcoma injected mice compared to control, p = 0.0231 (F). LAG3 + CD8+ expression was not significantly different between these two groups (G).
Figure 2 Naïve mice injected with in vivo treated α-PD-L1 mAb K7M2 cells are non-responsive to α-PD-L1 treatment, suggesting resistance to α-PD-L1 treatment. Naïve Balb/cJ mice were injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma, with decreased PD-L1 expression, (B) black histogram is PD-L1 expression prior to reimplantation in comparison to mock treated mice in white, and treated with α-PD-L1 mAb or mock (A). No significant difference was seen between survival in treated (n = 10) and untreated (n = 10) mice injected with treated metastatic osteosarcoma (C). PD-L1 expression on metastatic osteosarcoma from mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice was significantly decreased, p = 0.0026 (D). At time of necropsy, PD-1 + CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control K7M2 injected mice, p = 0.0017 (E). CTLA-4 + CD8+ expression was significantly different in in vivo α-PD-L1 mAb treated metastatic osteosarcoma injected mice compared to control, p = 0.0231 (F). LAG3 + CD8+ expression was not significantly different between these two groups (G).CC BY · PubMed Central
Figure 3 Dual α-CTLA-4/α-PD-L1 mAb treatment can completely eradicate metastatic osteosarcoma. Survival of combinational treatment of implantable metastatic osteosarcoma with α-CTLA-4 and α-PD-L1 mAb was significantly higher than α-PD-L1 mAb treatment alone, p = 0.0177. Additionally, survival of combination treatment α-CTLA-4/α-PD-L1 mAb compared to α-CTLA-4 mAb treatment alone was significantly different with a p value of p < 0.0001. α-CTLA-4 mAb alone was not significantly different than mock treated mice. N = 10 for all treatment groups.
Figure 3 Dual α-CTLA-4/α-PD-L1 mAb treatment can completely eradicate metastatic osteosarcoma. Survival of combinational treatment of implantable metastatic osteosarcoma with α-CTLA-4 and α-PD-L1 mAb was significantly higher than α-PD-L1 mAb treatment alone, p = 0.0177. Additionally, survival of combination treatment α-CTLA-4/α-PD-L1 mAb compared to α-CTLA-4 mAb treatment alone was significantly different with a p value of p < 0.0001. α-CTLA-4 mAb alone was not significantly different than mock treated mice. N = 10 for all treatment groups.CC BY · PubMed Central
Figure 4 Dual α-CTLA-4/α-PD-L1 mAb treatment can elicit protective immunity towards metastatic osteosarcoma. To evaluate protective immune responses to tumor, cured α-CTLA-4/α-PD-L1 mAb mice (n = 12) were challenged with 106 K7M2 cells at day 100. Cured α-CTLA-4/α-PD-L1 mAb treated mice cleared disease and significantly survived longer than age-matched control mice, p = 0.0049 (A). Lung tissue was evaluated for the presence of memory CD8 cells, and approximately 87% of the tumor-reactive memory T cells were CCR7 + CD62L+ (B). These CCR7 + CD62L + CD8+ cells were specific towards K7M2 cells used to generate the tumor, and able to produce IFNy and TNF in response to re-exposure, p=0.002 (C). To evaluate if protective immune responses to tumor were in fact due to memory CD8 T cells. Cured α-CTLA-4/α-PD-L1 mice (n = 6) were depleted of CD8 T cells at day 80, and challenged with 106 K7M2 cells after depletion. Mice depleted of CD8 T cells prior to challenge all succumbed to metastatic osteosarcoma in the lung tissue, in comparison to 100% survival (n = 6) in cured immune competent mice challenged. A log-rank test gives a p = 0.0177 (D).
Figure 4 Dual α-CTLA-4/α-PD-L1 mAb treatment can elicit protective immunity towards metastatic osteosarcoma. To evaluate protective immune responses to tumor, cured α-CTLA-4/α-PD-L1 mAb mice (n = 12) were challenged with 106 K7M2 cells at day 100. Cured α-CTLA-4/α-PD-L1 mAb treated mice cleared disease and significantly survived longer than age-matched control mice, p = 0.0049 (A). Lung tissue was evaluated for the presence of memory CD8 cells, and approximately 87% of the tumor-reactive memory T cells were CCR7 + CD62L+ (B). These CCR7 + CD62L + CD8+ cells were specific towards K7M2 cells used to generate the tumor, and able to produce IFNy and TNF in response to re-exposure, p=0.002 (C). To evaluate if protective immune responses to tumor were in fact due to memory CD8 T cells. Cured α-CTLA-4/α-PD-L1 mice (n = 6) were depleted of CD8 T cells at day 80, and challenged with 106 K7M2 cells after depletion. Mice depleted of CD8 T cells prior to challenge all succumbed to metastatic osteosarcoma in the lung tissue, in comparison to 100% survival (n = 6) in cured immune competent mice challenged. A log-rank test gives a p = 0.0177 (D).CC BY · PubMed Central
Figure 5 α-PD-L1 mAb treatment coupled with doxorubicin treatment does not enhance survival over α-PD-L1 mAb treatment alone. Survival of combinational treatment of metastatic osteosarcoma with doxorubicin and α-PD-L1 mAb was significantly higher than chemotherapy treated alone group, p = 0.0026, although no significant difference in survival was seen between combinational α-PD-L1 mAb and doxorubicin treatment and α-PD-L1 mAb alone. N = 10 for all treatment groups.
Figure 5 α-PD-L1 mAb treatment coupled with doxorubicin treatment does not enhance survival over α-PD-L1 mAb treatment alone. Survival of combinational treatment of metastatic osteosarcoma with doxorubicin and α-PD-L1 mAb was significantly higher than chemotherapy treated alone group, p = 0.0026, although no significant difference in survival was seen between combinational α-PD-L1 mAb and doxorubicin treatment and α-PD-L1 mAb alone. N = 10 for all treatment groups.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 206

Metadata

Authors
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N.
Affiliations
  • Arizona State University (US)
  • Phoenix Children's Hospital (US)
Corresponding author
Blattman, Joseph N
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2015-05-19
Volume
3
Issue
1
Pages
21-21
ISSN
2051-1426 (ISSN-L)
OpenAlex
W1543079591
Cited by
206
References
49
Citations by year
2026: 8 · 2025: 21 · 2024: 16 · 2023: 18 · 2022: 14 · 2021: 13 · 2020: 24 · 2019: 28 · 2018: 17 · 2017: 21 · 2016: 21 · 2015: 5
FWCI
9.32
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Arizona State University Library Digital Repository (Arizona State University) (submittedVersion)
Funders
Hyundai Hope On Wheels (0000-0003-2504-9663)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
metastatic osteosarcoma, combination immunotherapy, CTLA-4 blockade, PD-L1 blockade, PD-1/PD-L1 pathway, immune evasion, lung metastasis, tumor-infiltrating T cells, cancer immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. https://app.cochat.ai/papers/10.1186/s40425-015-0067-z
The paper
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015). Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-015-0067-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.